Condition: Psoriatic Arthritis · Sponsor: University of Pennsylvania
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
This description comes directly from the study's public registry record.
Sarah Gillespie · (215) 614-1840 · sarah.hopkins@pennmedicine.upenn.edu
Study Coordinator · SpAProgram@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Family Arthritis Center | Loxahatchee Groves, Florida, United States | Recruiting |
| Healing Rheumatology | Plant City, Florida, United States | Recruiting |
| Southwest Florida Rheumatology | Riverview, Florida, United States | Recruiting |
| Parris and Associates | Lilburn, Georgia, United States | Recruiting |
| University of Massachusetts Chan Medical School | Worcester, Massachusetts, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| New York University | New York, New York, United States | Recruiting |
| Cincy Arthritis | Blue Ash, Ohio, United States | Recruiting |
| Southern Ohio Rheumatology | Wheelersburg, Ohio, United States | Recruiting |
| Hospital at the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Cumberland Rheumatology | Crossville, Tennessee, United States | Recruiting |
| Heritage Rheumatology and Arthritis Care | Colleyville, Texas, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05669833